AcotiaMide
AcotiaMide Basic information
- Product Name:
- AcotiaMide
- Synonyms:
-
- AcotiaMide
- N-[2-[Bis(1-methylethyl)amino]ethyl]-2-[(2-hydroxy-4,5-dimethoxybenzoyl)amino]-4-thiazolecarboxamide
- N-(2-(diisopropylamino)ethyl)-2-(2-hydroxy-4,5-dimethoxybenzamido)thiazole-4-carboxamide hydrochloride
- ACOTIAMIDUM
- Acofide
- N-{2-[bis(1-methylethyl)amino]ethyl}-2-{[(2-hydroxy-4,5-dimethoxyphenyl)carbonyl]amino}-1,3-thiazole-4-carboxamide
- 4-Thiazolecarboxamide, N-[2-[bis(1-methylethyl)amino]ethyl]-2-[(2-hydroxy-4,5-dimethoxybenzoyl)amino]-
- Acotiamide formate salt
- CAS:
- 185106-16-5
- MF:
- C21H30N4O5S
- MW:
- 450.55
- Mol File:
- 185106-16-5.mol
AcotiaMide Chemical Properties
- Density
- 1.246±0.06 g/cm3(Predicted)
- storage temp.
- -20°C
- pka
- 7.38±0.50(Predicted)
- form
- powder
- color
- white to beige
- Water Solubility
- H2O: 20mg/mL, clear
AcotiaMide Usage And Synthesis
Uses
Acotiamide is an orally active, selective and reversible acetylcholinesterase (AChE) inhibitor, with an IC50 of 1.79 μM. Acotiamide can enhance gastric contractility and accelerate delayed gastric emptying. Acotiamide has the potential for the research of functional dyspepsia involving gastric motility dysfunction and intestinal inflammatory[1][2][3].
Definition
ChEBI: Acotiamide is a member of salicylamides.
Biological Activity
Acotiamide is a potent, selective and reversible inhibitor of human and canine stomach-derived acetylcholinesterase (AChE). Acotiamide showed no affinity for dopamine D2 or serotonin 5-HT4 receptors but does have activity as a muscarinic antagonist. It acts as a prokinetic drug through acetylcholinesterase inhibition and muscarinic receptor antagonism, and has been used for the treatment of functional dyspepsia (FD) involving gastric motility dysfunction.
in vivo
Acotiamide (0.3, 1, 3 mg/kg; i.v./3, 10, 30 mg/kg; p.o.) increases the postprandial gastric motility index in a dose-dependent manner[2].
Acotiamide (0.83 mg/kg; i.v.; once) inhibits AChE in rat stomach with an IC50 value of 1.79 μM[3].
| Animal Model: | Male mongrel dogs (9-11 kg), Male beagle dogs (9.6-12.9 kg)[2] |
| Dosage: | 0.3, 1, 3, 10, 30 mg/kg |
| Administration: | Intravenous injection; once |
| Result: | Increased the postprandial gastric motility. |
| Animal Model: | Male Sprague-Dawley rats (aged 6-7 weeks)[3] |
| Dosage: | 0.83 mg/kg |
| Administration: | Intravenous injection; once. |
| Result: | Effectively improved functional dyspepsia by inhibiting AChE in rat stomach. |
References
[1] Kazuyoshi Y oshii, et al. Physiologically-Based Pharmacokinetic and Pharmacodynamic Modeling for the Inhibition of Acetylcholinesterase by Acotiamide, A Novel Gastroprokinetic Agent for the Treatment of Functional Dyspepsia, in Rat Stomach. Pharmaceutical DOI:10.1007/s11095-015-1787-y
[2] Hiroshi Yamawaki, et al. Acotiamide attenuates central urocortin 2-induced intestinal inflammatory responses, and urocortin 2 treatment reduces TNF-α productions in LPS-stimulated macrophage cell lines. Neurogastroenterol Motil. 2020 Aug;32(8):e13813. DOI:10.1111/nmo.13813
[3] Matsunaga Y, Acotiamide hydrochloride (Z-338), a new selective acetylcholinesterase inhibitor, enhances gastric motility without prolonging QT interval in dogs: comparison with cisapride, itopride, and mosapride. J Pharmacol Exp Ther. 2011 Mar;336(3):791- DOI:10.1124/jpet.110.174847
AcotiaMideSupplier
- Tel
- 400-6009262 16621234537
- chenyj@titansci.com
- Tel
- 021-61551611 13296011611
- contact@trustwe.com
- Tel
- 025-57798810
- sales@sunlidabio.com
- Tel
- 021-57171705 13817537615
- sales@run-biotech.com
- Tel
- 0512-87182056 18013166090
- lingling.qi@yacoo.com.cn